Preliminary Full-Year 2024 Product Revenues Total $180.3 million, 15% Over 2023 Results and Exceed Prior Product Revenue Guidance 2025 Product Revenues Expected to be Between $194-$200 million, ...

Includes interest income/expense and foreign exchange gains/losses. ii. Represents revenue related to the cost reimbursement provisions under our government contracts. iii. Represents the direct ...

On January 19, 2026, Cerus Corporation announced that director Timothy L. Moore, whose current term runs until the company’s 2026 annual meeting of stockholders, has notified the board that he will ...

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company ...

Numbers may not sum due to rounding. Percentages calculated from unrounded figures. Hospital demand for IFC continues to increase with third quarter volumes (equivalent to FC15* therapeutic units) up ...

Company to Host Conference Call and Webcast on Wednesday, October 16, 2024 at 5:00 p.m. EDT The new BARDA contract will be funded in whole or in part with federal funds from the Department of Health ...

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the close of the stock market. The Company will ...

Cerus Corporation (NASDAQ:CERS) saw its stock climb 3.3% following news of a $7.2 million contract amendment from the U.S. Department of Defense (DoD). The new funding expands the company’s existing ...

William Bonello, an analyst from Craig-Hallum, has initiated a new Buy rating on Cerus (CERS). William Bonello has given his Buy rating due to a combination of factors that point to a promising future ...

Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: “The Cerus team delivered ...

Full-Year 2026 Product Revenue Expected to be $224 Million to $228 Million, Reflecting 9%-11% Growth, Year-Over-Year CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (CERS) today announced ...